Toll-like receptors (TLR) 7 and 8 are involved in the responses to viral and some bacterial infections. TLR7 and 8 display a high degree of similarity at the level of sequence as well as functionality. Both receptor types are located in the endosomal compartment and recognize single-stranded (ss) RNAs. Upon recognition of ssRNA, the TLR7/8 pathway is initiated via recruitment of MYD88 (myeloid differentiation primary response 88). The signaling cascade finally leads to the activation of the transcription factors NF-κB, AP-1, and/or IRF-7. Thus, the expression of pro-inflammatory cytokines and type I IFNs is triggered, which initiates the immune response. Apart from naturally occurring ligands, TLR7 and 8 can be activated by receptor agonists, like synthetic RNA oligoribonucleotides (ORNs) or small synthetic molecules of the imidazoquinoline family.
We provide high-quality ORNs for activation of either TLR7 only, TLR8 only, or TLR7 and TLR8 simultaneously, together with the respective controls. The control ORNs do not activate TLR7 or TLR8 and can serve as controls for backbone- or transfection reagent–related effects. We also offer the synthetic small molecule R848 (Resiquimod), which activates TLR7 and TLR8.
We provide high-quality ORNs for activation of either TLR7 only, TLR8 only, or TLR7 and TLR8 simultaneously, together with the respective controls. The control ORNs do not activate TLR7 or TLR8 and can serve as controls for backbone- or transfection reagent–related effects. We also offer the synthetic small molecule R848 (Resiquimod), which activates TLR7 and TLR8.